Profile
Eric Pottier worked as a Plant Manager at Eurand SpA.
He then worked as the Chief Pharmacist & Vice President-Supply Chain at Sangamo Therapeutics France SAS from 2014 to 2016.
Dr. Pottier holds a doctorate degree from L'Université d'Angers.
Former positions of Eric Pottier
| Companies | Position | End |
|---|---|---|
| TXCELL | Chief Operating Officer | 2013-12-31 |
Eurand SpA
 Eurand SpA Pharmaceuticals: MajorHealth Technology Eurand SpA is a specialty pharmaceutical company that develops, manufactures, and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. With integrated manufacturing and R&D facilities in the U.S. and Europe, the company has partnered with pharmaceutical companies licensing its four primary technology platforms: Customized Drug Release, Bioavailability Enhancement, Taste Masking or Oral Disintegrating Tablets, and Drug Conjugation. The company is headquartered in Pessano con Bornago, Italy. | Corporate Officer/Principal | - |
Training of Eric Pottier
| L'Université d'Angers | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Sangamo Therapeutics France SAS
 Sangamo Therapeutics France SAS Miscellaneous Commercial ServicesCommercial Services Sangamo Therapeutics France SAS is a biotechnology company, which engages in developing platforms for T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases. The company was founded on April 12, 2001, and is headquartered in Valbonne-Sophia Antipolis, France. | Commercial Services |
Eurand SpA
Eurand SpA Pharmaceuticals: MajorHealth Technology Eurand SpA is a specialty pharmaceutical company that develops, manufactures, and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. With integrated manufacturing and R&D facilities in the U.S. and Europe, the company has partnered with pharmaceutical companies licensing its four primary technology platforms: Customized Drug Release, Bioavailability Enhancement, Taste Masking or Oral Disintegrating Tablets, and Drug Conjugation. The company is headquartered in Pessano con Bornago, Italy. | Health Technology |
- Stock Market
- Insiders
- Eric Pottier
